Data on immunotherapeutic response predicted by TCIA demonstrated that high-risk ccRCC patients possessed a higher level of IPS to CTLA4 inhibitor and combination of PD1 and CTLA4 inhibitors than low-risk patients, indicating high-risk patients may respond better toward these two strategies of immunotherapies (Figure 8B). This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.